Loading clinical trials...
Loading clinical trials...
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer
Conditions
Interventions
ATEZOLIZUMAB
PERTUZUMAB
+1 more
Locations
2
United States
Northwestern University
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
May 21, 2018
Primary Completion Date
May 20, 2020
Completion Date
May 1, 2026
Last Updated
April 27, 2026
NCT06625775
NCT05800275
NCT06551116
NCT05230810
NCT06305702
NCT05042791
Lead Sponsor
Nancy Lin, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions